omarigliptin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co. It inhibits DPP-4 to increase incretin levels, which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.   Wikipedia

Chemistry

  • SMILES: CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2
  • InChIKey: MKMPWKUAHLTIBJ-ISTRZQFTSA-N
  • Mol. Mass: 398.44
  • ALogP: 1.14
  • ChEMBL Molecule:
    omarigliptin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4h)-yl)tetrahydro-2h-pyran-3-amine | marizev | mk3102 | mk-3102 | omarigliptin

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Glucose Intolerance (Phase 2)

Healthy Volunteers (Phase 1)

Kidney Failure, Chronic (Phase 1)

Renal Insufficiency, Chronic (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue